Skip to main navigation
Harrow Health

> Main Menu

About Our Company Our History Corporate Values Leadership Team Mission Work Corporate Transparency
Careers
Contact
Investors Overview News Events Letters to Stockholders Corporate Transparency Report Corporate Governance SEC Filings & Financials Stock Information Investor Resources

> Main Menu

About
Our Company Our History Corporate Values Leadership Team Mission Work Corporate Transparency
Careers Contact
Investors
Overview News Events Letters to Stockholders Corporate Transparency Report Corporate Governance SEC Filings & Financials Stock Information Investor Resources

Press Releases

February 15, 2023
Harrow Launches Next-Generation Compounded Atropine Formulations
February 2, 2023
Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023
January 23, 2023
Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products
January 5, 2023
Harrow Announces Availability of Fortisite™ Formulations for In-Office Use

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2
Displaying 11 - 14 of 14
Harrow Health

Address

102 Woodmont Blvd., Suite 610
Nashville, TN 37205

Phone

(615) 733 4730
(615) 733 4737 (Investor Relations)

Social

LinkedIn

© 2023 Harrow Health, Inc.

> Footer

Privacy Policy Cookie Notice